Clinical Report: Psychedelics in Chronic Pain Management and Medical Education
Overview
Psychedelics, including LSD and psilocybin, are gaining renewed interest for their therapeutic potential in chronic pain management amid evolving legal and societal landscapes. Despite promising research findings, formal medical education on psychedelics remains limited, highlighting the need for integrated curricula to prepare clinicians for future clinical applications.
Background
Classic psychedelics act primarily as 5HT2A receptor partial agonists, influencing brain areas involved in mood and perception. Historically used in cultural rituals, modern research has demonstrated their capacity to promote synaptic growth, anti-inflammatory effects, and disruption of neural networks implicated in psychiatric and pain conditions. Legal restrictions since the 1970 Controlled Substance Act have limited research, but recent FDA breakthrough therapy designations and increased public use have renewed scientific and clinical interest.
Data Highlights
Dose Level
Effects
Clinical Applications
Side Effects
Microdosing (Low)
Mild perceptual changes
ADHD, depression
Nausea, mood changes
Moderate Dose
Pronounced hallucinations, anxiety
Therapeutic exploration ongoing
Anxiety, physiological changes
Heroic/Macro Dose (High)
Intense hallucinations, cardiovascular effects
Depression, substance use disorders, end-of-life anxiety
Significant cardiovascular effects
Key Findings
Psychedelics primarily act as 5HT2A receptor partial agonists affecting mood and perception.
Research shows psychedelics promote synaptic growth, oxytocin release, and have anti-inflammatory properties.
FDA has granted breakthrough therapy designation to some psychedelics, facilitating research despite Schedule I status.
Medical education currently lacks standardized psychedelic curricula despite growing clinical interest and use.
A proposed curriculum includes preclinical foundational knowledge and clinical training with specialty-specific adaptations.
Ethical, legal, and cultural barriers remain significant challenges to clinical integration and education.
Clinical Implications
Clinicians should be aware of the evolving evidence supporting psychedelics for chronic pain and related conditions, alongside their complex legal status. Incorporating psychedelic education into medical training can enhance preparedness for future therapeutic use, ensuring safe, informed patient care and compliance with regulatory frameworks.
Conclusion
Psychedelics hold promising therapeutic potential for chronic pain management, but their safe clinical integration requires formalized education addressing pharmacology, legalities, and ethical considerations. Developing standardized curricula will equip future clinicians to navigate this emerging field effectively.
References
Clinical Perspectives, Resident & Fellow Forum -- Exploring the Evolution and Future Role of Psychedelics in Chronic Pain Management
by Christopher L Robinson, Pawan K Solanki, Sean Snyder, Adam Amir, Antje Barreveld, Rory Vu Mather, Ivo H Cerda, Michael Motoc, Harman Chopra, Robert Jason Yong, Joel Castellanos, Timothy Furnish, Alan D Kaye, Vwaire Orhurhu, Trent Emerick
